⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NVO News
Novo-Nordisk A/S
The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
globenewswire.com
LLY
NVO
VKTX
LGVN
Novo Nordisk’s oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 diabetes
globenewswire.com
NVO
PrecisionBiotics® (Novonesis) and Biocodex Mark Next Phase of Strategic Partnership with New Agreement
prnewswire.com
NVO
New funding opportunities pave the way for better diagnostics and treatment as well as for engineering efficient biosolutions and replacing critical and scarce resources
globenewswire.com
NVO
Connected Drug Delivery Devices Market Insights, Competitive Landscape, and Forecast Report 2025-2032: Rising Demand for Telehealth Programs Integrated with AR and Virtual Reality VR Technologies
globenewswire.com
MDT
WST
MRK
NVO
TNDM
TEVA
BDC
ImmunoForge to Accelerate CNS Drug Development with Innovative BBB Shuttle Platform 'LMT15'
prnewswire.com
NVO
GLP Diet App Launches Personalized Wellness App for GLP-1 Medication Users, Earns 2,500+ App Reviews
globenewswire.com
NVO
LLY
Dry Room Dehumidifier Market Report 2026 - Global Industry Size, Share, Trends, Opportunity, and Forecasts, 2021-2031
globenewswire.com
NVO
MU
MTX
Novo Nordisk A/S - share repurchase programme
globenewswire.com
NVO
Novo Nordisk: Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis events and improving haemoglobin response in sickle cell disease
globenewswire.com
NVO